BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin AS, Abbott DE, Hanseman D, Sussman JE, Kenkel A, Greiwe P, Saeed N, Ahmad SH, Sussman JJ, Ahmad SA. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. Ann Surg Oncol 2016;23:1941-7. [DOI: 10.1245/s10434-016-5109-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Angeles MA, Martínez-Gómez C, Del M, Migliorelli F, Daix M, Provendier A, Picard M, Ruiz J, Chantalat E, Leray H, Martinez A, Gladieff L, Ferron G. Risk factors for gastric perforation after cytoreductive surgery in patients with peritoneal carcinomatosis: Splenectomy and increased body mass index. PLoS One 2021;16:e0248205. [PMID: 33661999 DOI: 10.1371/journal.pone.0248205] [Reference Citation Analysis]
2 Li XB, Peng KW, Ji ZH, Yu Y, Liu G, Li Y. Prevention of Venous Thromboembolism After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Development of a Physiotherapy Program. Clin Appl Thromb Hemost 2019;25:1076029619890415. [PMID: 31775523 DOI: 10.1177/1076029619890415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Deschepper M, Vermeir P, Vogelaers D, Devulder J, Eeckloo K. Is pain at discharge a risk factor for unplanned hospital readmission? Acta Clinica Belgica 2016;72:95-102. [DOI: 10.1080/17843286.2017.1293311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Hübner M, Kusamura S, Villeneuve L, Al-Niaimi A, Alyami M, Balonov K, Bell J, Bristow R, Guiral DC, Fagotti A, Falcão LFR, Glehen O, Lambert L, Mack L, Muenster T, Piso P, Pocard M, Rau B, Sgarbura O, Somashekhar SP, Wadhwa A, Altman A, Fawcett W, Veerapong J, Nelson G. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations. Eur J Surg Oncol 2020;46:2311-23. [PMID: 32826114 DOI: 10.1016/j.ejso.2020.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
5 Rieser CJ, Hall LB, Kang E, Zureikat AH, Holtzman MP, Pingpank JF, Bartlett DL, Choudry MHA. Predischarge Prediction of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Derivation and Validation of a Risk Prediction Score. Ann Surg Oncol 2021;28:5287-96. [PMID: 33486643 DOI: 10.1245/s10434-020-09547-7] [Reference Citation Analysis]
6 Lee TC, Wima K, Morris MC, Winer LK, Sussman JJ, Ahmad SA, Patel SH. Incidence and Long-term Outcomes of Patients Requiring Early Reoperation After HIPEC. J Surg Res 2019;244:395-401. [PMID: 31325661 DOI: 10.1016/j.jss.2019.05.046] [Reference Citation Analysis]
7 Low CA, Bovbjerg DH, Ahrendt S, Choudry MH, Holtzman M, Jones HL, Pingpank JF Jr, Ramalingam L, Zeh HJ 3rd, Zureikat AH, Bartlett DL. Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission. Ann Behav Med 2018;52:88-92. [PMID: 29538623 DOI: 10.1093/abm/kax022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
8 Gabriel E, Singla S, Kim M, Fisher D, Powers C, Visioni A, Attwood K, Skitzki J. Water lavage as an adjunct to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Am J Surg 2017;214:462-7. [PMID: 28622839 DOI: 10.1016/j.amjsurg.2017.05.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Kyang LS, Alzahrani NA, Zhao J, Morris DL. Gastric perforation following cytoreductive surgery and perioperative intraperitoneal chemotherapy: a case series of six. World J Surg Oncol 2017;15:44. [PMID: 28187769 DOI: 10.1186/s12957-017-1114-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Dranichnikov P, Graf W, Cashin PH. Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-a national population-based study. World J Surg Oncol 2020;18:67. [PMID: 32252768 DOI: 10.1186/s12957-020-01837-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Kelly KJ, Cajas L, Baumgartner JM, Lowy AM. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2018;25:91-97. [PMID: 29090402 DOI: 10.1245/s10434-017-6108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
12 Lee TC, Wima K, Sussman JJ, Ahmad SA, Cloyd JM, Ahmed A, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Zaidi MY, Maithel SK, Leiting J, Grotz T, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Greer J, Patel SH. Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. J Gastrointest Surg 2020;24:165-76. [PMID: 31745888 DOI: 10.1007/s11605-019-04463-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
13 Moon EW, Wong JSM, See AHM, Ong WS, Tan CA, Ong CJ, Chia CS, Soo KC, Teo MCC, Tan GHC. Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2021. [PMID: 34304310 DOI: 10.1245/s10434-021-10414-2] [Reference Citation Analysis]
14 Paredes AZ, Abdel-misih S, Schmidt C, Dillhoff ME, Pawlik TM, Cloyd JM. Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Research 2019;234:103-9. [DOI: 10.1016/j.jss.2018.09.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Dreznik Y, Hoffman A, Hamburger T, Ben-Yaacov A, Dux Y, Jacoby H, Berger Y, Nissan A, Gutman M. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies. Surgeon 2018;16:278-82. [PMID: 29429947 DOI: 10.1016/j.surge.2018.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]